CARSGEN-B Receives IND Clearance from Chinese Drug Regulator for Novel Cell Therapy Targeting Lymphoma

Stock News08-07 08:12

CARSGEN-B (02171) has announced that its investigational cell therapy, CT1190B, has received clinical trial approval from China's National Medical Products Administration (NMPA).

This "off-the-shelf" CAR-T cell product, which targets both CD19 and CD20 antigens, is approved for patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) who have failed at least two prior lines of standard therapy.

Results from the investigator-initiated trial (IIT) for CT1190B were previously presented as a poster at the 2026 Annual Meeting of the European Hematology Association.

Developed using CARSGEN-B's proprietary THANK-u Plus® platform, CT1190B is a universal CAR-T cell therapy. It is currently being evaluated in an IIT for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1147606546?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 08:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1147606546","market":"sg","top_or_hot":-1,"title":"CARSGEN-B Receives IND Clearance from Chinese Drug Regulator for Novel Cell Therapy Targeting Lymphoma","media":"Stock News","content":"<p><b>CARSGEN-B</b> (02171) has announced that its investigational cell therapy, CT1190B, has received clinical trial approval from China's National Medical Products Administration (NMPA).<br><br>This \"off-the-shelf\" CAR-T cell product, which targets both CD19 and CD20 antigens, is approved for patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) who have failed at least two prior lines of standard therapy.<br><br>Results from the investigator-initiated trial (IIT) for CT1190B were previously presented as a poster at the 2026 Annual Meeting of the European Hematology Association.<br><br>Developed using <b>CARSGEN-B</b>'s proprietary THANK-u Plus® platform, CT1190B is a universal CAR-T cell therapy. It is currently being evaluated in an IIT for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CARSGEN-B Receives IND Clearance from Chinese Drug Regulator for Novel Cell Therapy Targeting Lymphoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCARSGEN-B Receives IND Clearance from Chinese Drug Regulator for Novel Cell Therapy Targeting Lymphoma\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-08-07 08:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>CARSGEN-B</b> (02171) has announced that its investigational cell therapy, CT1190B, has received clinical trial approval from China's National Medical Products Administration (NMPA).<br><br>This \"off-the-shelf\" CAR-T cell product, which targets both CD19 and CD20 antigens, is approved for patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) who have failed at least two prior lines of standard therapy.<br><br>Results from the investigator-initiated trial (IIT) for CT1190B were previously presented as a poster at the 2026 Annual Meeting of the European Hematology Association.<br><br>Developed using <b>CARSGEN-B</b>'s proprietary THANK-u Plus® platform, CT1190B is a universal CAR-T cell therapy. It is currently being evaluated in an IIT for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IND","symbol_name":"Xtrackers Nifty 500 India ETF","start_time":0,"source_url":"","article_id":"1147606546","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1147606546","pubTimestamp":1786061532,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CARSGEN-B (02171) has announced that its investigational cell therapy, CT1190B, has received clinical trial approval from China's National Medical Products Administration (NMPA).This \"off-the-shelf\"...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IND":"Xtrackers Nifty 500 India ETF","BK1161":"生物科技","BK1574":"生物医药B类股","BK1587":"次新股","02171":"科济药业-B","BK1585":"昨日强势股"},"translate_title":"CARSGEN-B 获得中国药品监管机构 IND 批准，用于靶向淋巴瘤的新型细胞疗法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02171":1,"IND":1},"content_text":"CARSGEN-B (02171) has announced that its investigational cell therapy, CT1190B, has received clinical trial approval from China's National Medical Products Administration (NMPA).This \"off-the-shelf\" CAR-T cell product, which targets both CD19 and CD20 antigens, is approved for patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) who have failed at least two prior lines of standard therapy.Results from the investigator-initiated trial (IIT) for CT1190B were previously presented as a poster at the 2026 Annual Meeting of the European Hematology Association.Developed using CARSGEN-B's proprietary THANK-u Plus® platform, CT1190B is a universal CAR-T cell therapy. It is currently being evaluated in an IIT for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1147606546","isCrawlerRequest":true}